Temozolomide

From Libre Pathology
Revision as of 15:04, 17 May 2017 by Michael (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Temozolomide is an oral alkylating agent used to treat glioma - especially glioblastoma.[1] The therapeutic effect is dependent on the O-6-methylguanine-DNA methyltransferase (MGMT) gene promotor methylation.

See also

References

  1. ↑ Stupp, R.; Hegi, ME.; Mason, WP.; van den Bent, MJ.; Taphoorn, MJ.; Janzer, RC.; Ludwin, SK.; Allgeier, A. et al. (May 2009). "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.". Lancet Oncol 10 (5): 459-66. doi:10.1016/S1470-2045(09)70025-7. PMID 19269895.
Retrieved from "https://librepathology.org/w/index.php?title=Temozolomide&oldid=47395"